Treatment advances in antiphospholipid syndrome: 2022 update. (August 2022)

• Record Type: Journal Article
• Authors: Erton, Zeynep Belce; Erkan, Doruk
• Is Part Of: Current opinion in pharmacology. Volume 65(2022)
• Publication Date: 2022-08
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2022.102212
• Languages: English
• ISSNs: 1471-4892

Abstract

Abstract: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or non-thrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional treatment strategies of antiphospholipid syndrome focuses on antithrombotic agents, however they are usually not effective for microvascular and non-thrombotic manifestations of aPL. In parallel to our increased understanding of the mechanisms of aPL-mediated clinical events, immunosuppression has been increasingly used in aPL-positive patients. This review focuses on the role of potential targeted immunosuppressive treatments in APS (B-cell inhibition, complement inhibition, mechanistic target of rapamycin inhibition, and traditional rheumatologic disease–modifying agents including hydroxychloroquine) and future perspectives.